J 2023

A comprehensive molecular analysis of 113 primary ovarian clear cell carcinomas reveals common therapeutically significant aberrations

STRUZINSKA, Ivana, Nikola HAJKOVA, Jan HOJNY, Eva KRKAVCOVA, Romana MICHALKOVA et. al.

Basic information

Original name

A comprehensive molecular analysis of 113 primary ovarian clear cell carcinomas reveals common therapeutically significant aberrations

Authors

STRUZINSKA, Ivana (203 Czech Republic, guarantor), Nikola HAJKOVA (203 Czech Republic), Jan HOJNY (203 Czech Republic), Eva KRKAVCOVA (203 Czech Republic), Romana MICHALKOVA (203 Czech Republic), Jiri DVORAK (203 Czech Republic), Kristyna NEMEJCOVA (203 Czech Republic), Radoslav MATEJ (203 Czech Republic), Jan LACO (203 Czech Republic), Jana DROZENOVA (203 Czech Republic), Pavel FABIAN (203 Czech Republic), Jitka HAUSNEROVÁ (203 Czech Republic, belonging to the institution), Gabor MEHES (203 Czech Republic), Petr SKAPA (203 Czech Republic), Marian SVAJDLER (203 Czech Republic), David CIBULA (203 Czech Republic), Filip FRUHAUF (203 Czech Republic), Michaela Kendall KENDALL BARTU (203 Czech Republic) and Pavel DUNDR (203 Czech Republic)

Edition

Diagnostic Pathology, LONDON, BMC, 2023, 1746-1596

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30109 Pathology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.600 in 2022

RIV identification code

RIV/00216224:14110/23:00131201

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1186/s13000-023-01358-0

UT WoS

001002555100001

Keywords in English

Capture DNA NGS; RNA-Seq; Rare ovarian tumors; POLE mutation

Tags

14110230, rivok

Tags

International impact, Reviewed
Změněno: 12/1/2024 13:29, Mgr. Tereza Miškechová

Abstract

V originále

BackgroundMolecular aberrations occurring in primary ovarian clear cell carcinoma (OCCC) can be of diagnostic, predictive, and prognostic significance. However, a complex molecular study including genomic and transcriptomic analysis of large number of OCCC has been lacking.Methods113 pathologically confirmed primary OCCCs were analyzed using capture DNA NGS (100 cases; 727 solid cancer related genes) and RNA-Seq (105 cases; 147 genes) in order to describe spectra and frequency of genomic and transcriptomic alterations, as well as their prognostic and predictive significance.ResultsThe most frequent mutations were detected in genes ARID1A, PIK3CA, TERTp, KRAS, TP53, ATM, PPP2R1A, NF1, PTEN, and POLE (51,47,27,18,13,10,7,6,6, and 4%, respectively). TMB-High cases were detected in 9% of cases. Cases with POLEmut and/or MSI-High had better relapse-free survival. RNA-Seq revealed gene fusions in 14/105 (13%) cases, and heterogeneous expression pattern. The majority of gene fusions affected tyrosine kinase receptors (6/14; four of those were MET fusions) or DNA repair genes (2/14). Based on the mRNA expression pattern, a cluster of 12 OCCCs characterized by overexpression of tyrosine kinase receptors (TKRs) AKT3, CTNNB1, DDR2, JAK2, KIT, or PDGFRA (p < 0.00001) was identified.ConclusionsThe current work has elucidated the complex genomic and transcriptomic molecular hallmarks of primary OCCCs. Our results confirmed the favorable outcomes of POLEmut and MSI-High OCCC. Moreover, the molecular landscape of OCCC revealed several potential therapeutical targets. Molecular testing can provide the potential for targeted therapy in patients with recurrent or metastatic tumors.

Links

90233, large research infrastructures
Name: BBMRI.cz IV
Displayed: 13/11/2024 07:41